Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10

Authors
Hong, Sook HeeLee, SoohyeonKim, Hoon-GuLee, Hyo JinJung, Kyung HaeLee, Sang-CheolLee, Na-RiYun, JinaWoo, In SookPark, Kyong HwaKim, Kyoung-haKim, Ho YoungRha, Sun YoungByun, Jae Ho
Issue Date
2월-2015
Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
Keywords
Platinum resistant; Ovarian cancer; Gemcitabine; Vinorelbine
Citation
GYNECOLOGIC ONCOLOGY, v.136, no.2, pp.212 - 217
Indexed
SCIE
SCOPUS
Journal Title
GYNECOLOGIC ONCOLOGY
Volume
136
Number
2
Start Page
212
End Page
217
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/94506
DOI
10.1016/j.ygyno.2014.11.017
ISSN
0090-8258
Abstract
Objective. The main aim of this study was to evaluate the antitumor activity and safety of vinorelbine and gemcitabine combination chemotherapy in patients with primary refractory or recurrent platinum-resistant epithelial ovarian and primary peritoneal cancers. Methods. Patients with platinum-resistant or primary refractory disease were eligible. Patients were allowed one prior chemotherapy for the treatment of platinum-resistant or refractory disease. Vinorelbine 25 mg/m(2), followed by gemcitabine 1000 mg/m(2), was administered intravenously on days 1 and 8 every 3 weeks. Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 and cancer antigen 125 test (CA-125 criteria) were adopted to classify responses. Results. 44 patients received the median of 4 (range, 1-24) treatments with fifteen (34.1%) receiving six or more cycles. The overall objective response rate was 22.7%. One patient (2.3%) had complete while 9 patients (20.4%) had partial responses with median duration of response of 5.9 months. 17 patients (38.6%) had stable disease for a median of 3.3 months. Median progression-free survival (PFS) was 3.4 months and overall survival (OS) was 14.5 months. Four (9.1%) patients were not assessable. Neutropenia was the most frequently encountered toxicity, with grade 3 or 4 observed in 22 patients (50.0%). Fifteen patients (34.1%) needed immediate dose reduction. No treatment related death was reported. Conclusions. The combination chemotherapy with gemcitabine and vinorelbine achieved the primary end point of our clinical trial in management of platinum resistant recurrent ovarian cancer. However, further sophisticated dosing and scheduling of combination chemotherapy are needed because of a significant proportion of dose reduction. (C) 2014 Elsevier Inc. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
Graduate School > Department of Biomedical Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Kyong Hwa photo

Park, Kyong Hwa
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE